WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTN) reported the positive effects of PL8177 on treating ulcerative colitis in an animal disease model, including genomic data characterizing the anti-inflammatory effects of melanocortin agonists. The company said the data showed that orally administered PL8177 improved markers of colitis compared to the vehicle group. The company said the results support the aim of ultimately treating inflammatory bowel disease in humans.
Palatin Technologies is planning to conduct a phase 2 clinical study evaluating PL8177 administered orally as a treatment for ulcerative colitis later in the year.
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
PALATIN TECHNOLOGIES-Aktie komplett kostenlos handeln - auf Smartbroker.de